Showing results (221-230 of 243) with videos related to
Sort By:
Pageof 25
Molecular Cancer|October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX developmentDamien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-AnalysisLeonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non-Small Cell Lung CancerSandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.Pageof 25